ArticleDiscover oncology2025
Incidence of pulmonary embolism and its risk factors in lung cancer patients: a systematic review and meta-analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Subclinical pulmonary embolism in first-line/induction therapy of lung cancer - a remaining clinically relevant adverse event.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePulmonary embolism (PE) not only threatens quality of life (QOL) but also poses a direct threat to life itself. This study was aimed at evaluating the incidence of PE and its risk factors in LC patients by meta-analysis (MA).
methodsA search was done in electronic databases such as PubMed, EMBASE, Web of Science, and the Cochrane Library. Quality assessment was performed using the Newcastle Ottawa Scale (NOS). MA was conducted using Stata16.0.
resultsA total of 18 studies were included with a sample size of 216,344 in total. The incidence of PE in LC patients was 8.3% (95% CI 6.9%-9.6%). Risk factors for PE in LC patients included adenocarcinoma as a pathologic type (OR = 2.61, 95% CI 1.87-5.11), the advanced stage as a tumor stage (OR = 2.15, 95% CI 1.90-3.63), chemotherapy (OR = 2.42, 95% CI 1.86-3.72), concomitant DVT (OR = 4.42,95% CI 2.56-11.68), hemoglobin ≥ 140 g/L (OR = 2.25, 95% CI 2.10-4.60), D-dimer ≥ 500 mmol/L (OR = 4.27, 95% CI 1.76-24.34), and elevated CEA (OR = 2.69, 95% CI 1.85-3.93).
conclusionPE is a common complication in LC patients. Close follow-up and a comprehensive screening program are important, especially for high-risk patients who receive chemotherapy or have advanced cancer, adenocarcinoma, concomitant DVT, or high levels of hemoglobin/D-dimer/CEA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.